Mixed Origins: HIV gp120-Specific Memory Develops from Pre-Existing Memory and Naive B Cells Following Vaccination in Humans

AIDS Res Hum Retroviruses. 2023 Jul;39(7):350-366. doi: 10.1089/AID.2022.0104. Epub 2023 Mar 22.

Abstract

The most potent and broad HIV envelope (Env)-specific antibodies often when reverted to their inferred germline versions representing the naive B cell receptor, fail to bind Env, suggesting that the initial responding B cell population not only exclusively comprises a naive population, but also a pre-existing cross-reactive antigen-experienced B cell pool that expands following Env exposure. Previously we isolated gp120-reactive monoclonal antibodies (mAbs) from participants in HVTN 105, an HIV vaccine trial. Using deep sequencing, focused on immunoglobulin G (IgG), IgA, and IgM, VH-lineage tracking, we identified four of these mAb lineages in pre-immune peripheral blood. We also looked through the ∼7 month postvaccination bone marrow, and interestingly, several of these lineages that were found in prevaccination blood were still persistent in the postvaccination bone marrow, including the CD138+ long-lived plasma cell compartment. The majority of the pre-immune lineage members included IgM, however, IgG and IgA members were also prevalent and exhibited somatic hypermutation. These results suggest that vaccine-induced gp120-specific antibody lineages originate from both naive and cross-reactive memory B cells. ClinicalTrials.gov NCT02207920.

Keywords: B cell; HIV-1; antibody repertoire; envelope; gp120; memory; naive; pre-immune.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • AIDS Vaccines*
  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • HIV Antibodies
  • HIV Envelope Protein gp120
  • HIV Infections* / prevention & control
  • HIV-1*
  • Humans
  • Immunoglobulin A
  • Immunoglobulin G
  • Immunoglobulin M
  • Vaccination

Substances

  • HIV Antibodies
  • HIV Envelope Protein gp120
  • Immunoglobulin G
  • Antibodies, Monoclonal
  • AIDS Vaccines
  • Immunoglobulin A
  • Immunoglobulin M
  • Antibodies, Neutralizing

Associated data

  • ClinicalTrials.gov/NCT02207920